This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To examine the effect of an imperceptible level of galvanic vestibular stimulation (GVS), delivered as zero-mean current noise (noisy GVS), on postural performance in healthy subjects as well as in patients with bilateral peripheral vestibular dysfunction.
Methods: White noise GVS with an amplitude ranging from 0 to 1,000 μA was applied in 21 healthy subjects and 11 patients with bilateral vestibular dysfunction. Two-legged stance tasks were performed with the eyes closed during a 60-second period, which consisted of a baseline period without stimulation and a stimulation period with GVS. We examined 3 parameters: the velocity, the envelopment area, and the root mean square (RMS) of the center of pressure.
Results: White noise GVS improved all 3 parameters in 76% of healthy subjects. The amplitude of the optimal stimulus was 281 ± 40 μA, and it improved the velocity, area, and RMS by 18.4% ± 2%, 37.9% ± 3.5%, and 20.4% ± 2.2%, respectively (p < 0.01). The GVS improved all 3 parameters in 91% of patients. The amplitude of the optimal stimulus was 456 ± 82 μA, and it improved the velocity, area, and RMS by 29.4% ± 4.9%, 45.6% ± 4.7%, and 22% ± 3.3%, respectively (p < 0.01).
Conclusions: Noisy GVS is effective in improving postural stability in healthy subjects as well as in patients with bilateral vestibular dysfunction.
Classification of evidence: This study provides Class IV evidence that in patients with bilateral vestibular dysfunction, an imperceptible level of noisy GVS may improve postural stability.
GLOSSARY
- COP=
- center of pressure;
- GVS=
- galvanic vestibular stimulation;
- RMS=
- root mean square;
- SR=
- stochastic resonance
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received July 21, 2013.
- Accepted in final form December 2, 2013.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience
Dr. Henry J. Kaminski and Dr. Sarah Wright